Lupin inks agreement with Spektus to commercialise novel antidepressant DeslaFlex™ in Canada

image credit- freepik

Global pharma major Lupin Limited has signed a licence and supply agreement with Spektus Pharma, a specialty pharmaceutical company to commercialise the novel antidepressant DeslaFlex™ in Canada.

DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab™ oral drug-delivery platform.

This strategic partnership combines Lupin’s strong commercial footprint in Canada and Spektus’s capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex™ and establish a robust platform for future launches.

The collaboration further strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.

“This milestone reinforces our long-term commitment to advancing Lupin’s CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalised, patient-focused care,” said Claus Jepsen, President, Global Specialty, Lupin.

Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said, “This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin’s global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex™ for patients across this important market.”